Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
June 04, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
January 08, 2020 13:36 ET
|
Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
December 13, 2017 13:13 ET
|
Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...
Rafarma Pharmaceuticals (RAFA) Commences Preparation of Audited Financials
May 12, 2014 09:15 ET
|
Rafarma Pharmaceuticals, Inc.
MOSCOW, May 12, 2014 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (Pink Sheets:RAFA) has commenced a formal audit to provide additional transparency in its public filings with a forward view to...